116 related articles for article (PubMed ID: 38113425)
21. The Prognostic Effect of
Østergaard A; Enshaei A; Pieters R; Vora A; Horstmann MA; Escherich G; Johansson B; Heyman M; Schmiegelow K; Hoogerbrugge PM; den Boer ML; Kuiper RP; Moorman AV; Boer JM; van Leeuwen FN
Hemasphere; 2023 May; 7(5):e875. PubMed ID: 37153875
[No Abstract] [Full Text] [Related]
22. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report.
Martinelli G; Iacobucci I; Storlazzi CT; Vignetti M; Paoloni F; Cilloni D; Soverini S; Vitale A; Chiaretti S; Cimino G; Papayannidis C; Paolini S; Elia L; Fazi P; Meloni G; Amadori S; Saglio G; Pane F; Baccarani M; Foà R
J Clin Oncol; 2009 Nov; 27(31):5202-7. PubMed ID: 19770381
[TBL] [Abstract][Full Text] [Related]
23. RAS pathway mutation is an added-value biomarker in pediatric Philadelphia-negative B-cell acute lymphoblastic leukemia with IKZF1 deletions.
Huang YJ; Liu HC; Jaing TH; Wu KH; Wang SC; Yen HJ; Hsiao CC; Chen SH; Lin PC; Yeh TC; Sheen JM; Chen YC; Chang TK; Huang FL; Chao YH; Hou JY; Yang CP; Lin TH; Shih LY
Pediatr Blood Cancer; 2021 Apr; 68(4):e28899. PubMed ID: 33522704
[TBL] [Abstract][Full Text] [Related]
24. Association of Combined Focal 22q11.22 Deletion and IKZF1 Alterations With Outcomes in Childhood Acute Lymphoblastic Leukemia.
Mangum DS; Meyer JA; Mason CC; Shams S; Maese LD; Gardiner JD; Downie JM; Pei D; Cheng C; Gleason A; Luo M; Pui CH; Aplenc R; Hunger SP; Loh M; Greaves M; Trede N; Raetz E; Frazer JK; Mullighan CG; Engel ME; Miles RR; Rabin KR; Schiffman JD
JAMA Oncol; 2021 Oct; 7(10):1521-1528. PubMed ID: 34410295
[TBL] [Abstract][Full Text] [Related]
25. IKZF1
Stanulla M; Dagdan E; Zaliova M; Möricke A; Palmi C; Cazzaniga G; Eckert C; Te Kronnie G; Bourquin JP; Bornhauser B; Koehler R; Bartram CR; Ludwig WD; Bleckmann K; Groeneveld-Krentz S; Schewe D; Junk SV; Hinze L; Klein N; Kratz CP; Biondi A; Borkhardt A; Kulozik A; Muckenthaler MU; Basso G; Valsecchi MG; Izraeli S; Petersen BS; Franke A; Dörge P; Steinemann D; Haas OA; Panzer-Grümayer R; Cavé H; Houlston RS; Cario G; Schrappe M; Zimmermann M; ;
J Clin Oncol; 2018 Apr; 36(12):1240-1249. PubMed ID: 29498923
[TBL] [Abstract][Full Text] [Related]
26. IKZF1 Deletion Subtyping and Outcome Analysis in BCR-ABL1-Negative Pediatric B-Cell Acute Lymphoblastic Leukemia: A Single-Institution Experience from North India.
Gupta SK; Bakhshi S; Gupta R; Sharma P; Pushpam D; Sahoo RK; Kamal VK
Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):e666-e673. PubMed ID: 33906825
[TBL] [Abstract][Full Text] [Related]
27. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.
van der Veer A; Waanders E; Pieters R; Willemse ME; Van Reijmersdal SV; Russell LJ; Harrison CJ; Evans WE; van der Velden VH; Hoogerbrugge PM; Van Leeuwen F; Escherich G; Horstmann MA; Mohammadi Khankahdani L; Rizopoulos D; De Groot-Kruseman HA; Sonneveld E; Kuiper RP; Den Boer ML
Blood; 2013 Oct; 122(15):2622-9. PubMed ID: 23974192
[TBL] [Abstract][Full Text] [Related]
28. Combined IKZF1 and IG markers as new tools for diagnosis and minimal residual disease assessment in Tunisian B-ALL.
Besbes S; Hamadou WS; Boulland ML; Lefranc MP; Ben Youssef Y; Achour B; Khelif A; Fest T; Soua Z
Bull Cancer; 2016 Oct; 103(10):822-828. PubMed ID: 27614734
[TBL] [Abstract][Full Text] [Related]
29. Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort study.
Michels N; Boer JM; Enshaei A; Sutton R; Heyman M; Ebert S; Fiocco M; de Groot-Kruseman HA; van der Velden VHJ; Barbany G; Escherich G; Vora A; Trahair T; Dalla-Pozza L; Pieters R; Zur Stadt U; Schmiegelow K; Moorman AV; Zwaan CM; den Boer ML
Lancet Haematol; 2021 Oct; 8(10):e700-e710. PubMed ID: 34560013
[TBL] [Abstract][Full Text] [Related]
30. The clinical impact of IKZF1 deletions in paediatric B-cell precursor acute lymphoblastic leukaemia is independent of minimal residual disease stratification in Nordic Society for Paediatric Haematology and Oncology treatment protocols used between 1992 and 2013.
Olsson L; Ivanov Öfverholm I; Norén-Nyström U; Zachariadis V; Nordlund J; Sjögren H; Golovleva I; Nordgren A; Paulsson K; Heyman M; Barbany G; Johansson B
Br J Haematol; 2015 Sep; 170(6):847-58. PubMed ID: 26018335
[TBL] [Abstract][Full Text] [Related]
31. Selected miRNA levels are associated with
Krzanowski J; Madzio J; Pastorczak A; Tracz A; Braun M; Tabarkiewicz J; Pluta A; Młynarski W; Zawlik I
Oncol Lett; 2017 Sep; 14(3):3853-3861. PubMed ID: 28927157
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study.
Boer JM; van der Veer A; Rizopoulos D; Fiocco M; Sonneveld E; de Groot-Kruseman HA; Kuiper RP; Hoogerbrugge P; Horstmann M; Zaliova M; Palmi C; Trka J; Fronkova E; Emerenciano M; do Socorro Pombo-de-Oliveira M; Mlynarski W; Szczepanski T; Nebral K; Attarbaschi A; Venn N; Sutton R; Schwab CJ; Enshaei A; Vora A; Stanulla M; Schrappe M; Cazzaniga G; Conter V; Zimmermann M; Moorman AV; Pieters R; den Boer ML
Leukemia; 2016 Jan; 30(1):32-8. PubMed ID: 26202931
[TBL] [Abstract][Full Text] [Related]
33. IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.
Dörge P; Meissner B; Zimmermann M; Möricke A; Schrauder A; Bouquin JP; Schewe D; Harbott J; Teigler-Schlegel A; Ratei R; Ludwig WD; Koehler R; Bartram CR; Schrappe M; Stanulla M; Cario G
Haematologica; 2013 Mar; 98(3):428-32. PubMed ID: 22875627
[TBL] [Abstract][Full Text] [Related]
34.
Lopes BA; Barbosa TC; Souza BKS; Poubel CP; Pombo-de-Oliveira MS; Emerenciano M;
Cancer Prev Res (Phila); 2017 Dec; 10(12):738-744. PubMed ID: 28947432
[TBL] [Abstract][Full Text] [Related]
35. IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL.
van der Veer A; Zaliova M; Mottadelli F; De Lorenzo P; Te Kronnie G; Harrison CJ; Cavé H; Trka J; Saha V; Schrappe M; Pieters R; Biondi A; Valsecchi MG; Stanulla M; den Boer ML; Cazzaniga G
Blood; 2014 Mar; 123(11):1691-8. PubMed ID: 24366361
[TBL] [Abstract][Full Text] [Related]
36. Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients.
Scheijen B; Boer JM; Marke R; Tijchon E; van Ingen Schenau D; Waanders E; van Emst L; van der Meer LT; Pieters R; Escherich G; Horstmann MA; Sonneveld E; Venn N; Sutton R; Dalla-Pozza L; Kuiper RP; Hoogerbrugge PM; den Boer ML; van Leeuwen FN
Haematologica; 2017 Mar; 102(3):541-551. PubMed ID: 27979924
[TBL] [Abstract][Full Text] [Related]
37. The many faces of IKZF1 in B-cell precursor acute lymphoblastic leukemia.
Marke R; van Leeuwen FN; Scheijen B
Haematologica; 2018 Apr; 103(4):565-574. PubMed ID: 29519871
[TBL] [Abstract][Full Text] [Related]
38. Developmental origins and impact of BCR-ABL1 fusion and IKZF1 deletions in monozygotic twins with Ph+ acute lymphoblastic leukemia.
Cazzaniga G; van Delft FW; Lo Nigro L; Ford AM; Score J; Iacobucci I; Mirabile E; Taj M; Colman SM; Biondi A; Greaves M
Blood; 2011 Nov; 118(20):5559-64. PubMed ID: 21960589
[TBL] [Abstract][Full Text] [Related]
39. Loss-of-function but not dominant-negative intragenic
Kobitzsch B; Gökbuget N; Schwartz S; Reinhardt R; Brüggemann M; Viardot A; Wäsch R; Starck M; Thiel E; Hoelzer D; Burmeister T
Haematologica; 2017 Oct; 102(10):1739-1747. PubMed ID: 28751559
[TBL] [Abstract][Full Text] [Related]
40. IKZF1 (IKAROS) deletions in B-ALL and its clinical correlation: A prospective study from a tertiary care centre in Northern India.
Gupta SK; Bakhshi S; Kumar L; Seth R; Kumar R
Leuk Res; 2016 Feb; 41():7-11. PubMed ID: 26704074
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
